Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$471.11 USD
+3.11 (0.66%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $471.15 +0.04 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Company Summary
Boston, MA-based Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company’s main area of focus is cystic fibrosis (CF).
The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor/ivacaftor and ivacaftor), Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat nearly 75% of the 92,000 people with CF in North America, Europe and Australia. Trikafta/Kaftrio (brand name of Trikafta in EU), Vertex’s triple combination regimen, is approved for the ...
Company Summary
Boston, MA-based Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company’s main area of focus is cystic fibrosis (CF).
The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor/ivacaftor and ivacaftor), Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat nearly 75% of the 92,000 people with CF in North America, Europe and Australia. Trikafta/Kaftrio (brand name of Trikafta in EU), Vertex’s triple combination regimen, is approved for the treatment of CF in people aged 2 years and older who have at least one F508del mutation in the United States and for CF patients aged 6 and above in countries outside the United States.
In 2023/early 2024, Vertex received regulatory approvals for its one-shot gene therapy Casgevy for treating two debilitating blood disorders, sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), in the United States and European Union and some other countries like Great Britain, Bahrain and the Kingdom of Saudi Arabia.
While CF remains the main area of focus, Vertex is also developing treatments for acute and neuropathic pain, APOL1-mediated kidney disease, type I diabetes, myotonic dystrophy type 1, alpha-1 antitrypsin deficiency and autosomal dominant polycystic kidney disease (“ADPKD”).
Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen in 2014 while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA in 2017.
The company recorded total revenues of $9.87 billion in 2023, up 11% year over year. Trikafta/ Kaftrio accounted for more than 90% of the company’s total product revenues and generated $8.94 billion in sales in 2023.
General Information
Vertex Pharmaceuticals Incorporated
50 NORTHERN AVENUE
BOSTON, MA 02210
Phone: 617-341-6100
Fax: 617-576-2109
Web: http://www.vrtx.com
Email: investorinfo@vrtx.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/4/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 4.11 |
Current Year EPS Consensus Estimate | 0.36 |
Estimated Long-Term EPS Growth Rate | 12.50 |
Exp Earnings Date | 11/4/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 468.00 |
52 Week High | 510.64 |
52 Week Low | 341.85 |
Beta | 0.40 |
20 Day Moving Average | 1,012,199.12 |
Target Price Consensus | 506.11 |
4 Week | -0.10 |
12 Week | -2.65 |
YTD | 15.02 |
4 Week | -1.28 |
12 Week | -2.23 |
YTD | 1.44 |
Shares Outstanding (millions) | 258.10 |
Market Capitalization (millions) | 120,791.83 |
Short Ratio | NA |
Last Split Date | 8/24/2000 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 1,318.31 |
Trailing 12 Months | 2,228.57 |
PEG Ratio | 105.46 |
vs. Previous Year | -475.92% |
vs. Previous Quarter | -409.32% |
vs. Previous Year | 6.11% |
vs. Previous Quarter | -1.67% |
Price/Book | 8.17 |
Price/Cash Flow | 31.93 |
Price / Sales | 11.68 |
6/30/24 | -2.45 |
3/31/24 | 23.08 |
12/31/23 | 21.91 |
6/30/24 | -1.87 |
3/31/24 | 17.71 |
12/31/23 | 16.73 |
6/30/24 | 2.52 |
3/31/24 | 3.50 |
12/31/23 | 3.99 |
6/30/24 | 2.26 |
3/31/24 | 3.29 |
12/31/23 | 3.78 |
6/30/24 | -4.00 |
3/31/24 | 38.58 |
12/31/23 | 35.51 |
6/30/24 | -4.74 |
3/31/24 | 39.46 |
12/31/23 | 36.68 |
6/30/24 | 2.08 |
3/31/24 | 46.81 |
12/31/23 | 44.38 |
6/30/24 | 57.25 |
3/31/24 | 71.76 |
12/31/23 | 68.22 |
6/30/24 | 1.78 |
3/31/24 | 1.88 |
12/31/23 | 1.97 |
6/30/24 | 0.02 |
3/31/24 | 0.02 |
12/31/23 | 0.02 |
6/30/24 | 2.29 |
3/31/24 | 1.91 |
12/31/23 | 2.09 |